Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 CAR-T in PR Relapsed/Refractory Mantle-Cell Lymphoma on Ibrutinib
2022-502907-31-00Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jun 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Complete response rate at 90 days. Started Jun 2023; status: terminated.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2022-502907-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502907-31-00.